Clinical trials of varicella vaccine in healthy adolescents and adults
| Autor: | Allan Arbeter |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Microbiology (medical)
Adult Pediatrics medicine.medical_specialty Varicella vaccine Adolescent viruses Population Herpes Zoster Virus Chickenpox Vaccine Chickenpox Japan Medicine Humans Seroconversion education education.field_of_study Clinical Trials as Topic integumentary system business.industry Antibody titer virus diseases medicine.disease United States Clinical trial Pneumonia Infectious Diseases business Encephalitis |
| Zdroj: | Infectious disease clinics of North America. 10(3) |
| ISSN: | 0891-5520 |
| Popis: | From the beginning of laboratory development and clinical trials of the varicella vaccines, immunizations of adolescents and adults have been of priority consideration because of the disproportionately high morbidity and mortality of natural varicella in these populations. Although not frequent, the increased risk of secondary complications such as pneumonia, encephalitis, physician visits, hospitalizations, and death in the adult has been substantiated in population-based surveys.h* With the increased use of daycare and nursery programs for young children, an increased opportunity for virus spread to their parents, caretakers, and teachers has occurred. The increased number of health care workers caring for patients with reactivation of latent varicella-zoster virus (VZV) infection has also increased the number of adults exposed to varicella. Those who are susceptible are at risk of severe clinical disease. In contrast to the immunogenicity of varicella vaccine in healthy children, adolescents and adults require a two-injection schedule to have similar seroconversion rates and antivaricella antibody titers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|